Mechanisms of chiropractic spinal manipulative therapy for patients with chronic primary low back pain: Protocol for a mechanistic randomised placebo-controlled trial

Gevers-Montoro, C., Ortega-De Mues, A. et Piché, M. (2023). Mechanisms of chiropractic spinal manipulative therapy for patients with chronic primary low back pain: Protocol for a mechanistic randomised placebo-controlled trial. BMJ Open, 13 (2). e065999. ISSN 2044-6055 DOI 10.1136/bmjopen-2022-065999

Prévisualisation

PDF Télécharger (2MB) | Prévisualisation

Résumé

Introduction
Chronic low back pain (CLBP) is a highly prevalent and disabling condition. Identifying subgroups of patients afflicted with CLBP is a current research priority, for which a classification system based on pain mechanisms was proposed. Spinal manipulative therapy (SMT) is recommended for the management of CLBP. Yet, little data are available regarding its mechanisms of action, making it difficult to match this intervention to the patients who may benefit the most. It was suggested that SMT may influence mechanisms associated with central sensitisation. Therefore, classifying patients with CLBP according to central sensitisation mechanisms may help predict their response to SMT.

Methods and analysis
This protocol describes a randomised placebo-controlled trial aiming to examine which variables linked to central sensitisation may help predict the clinical response to SMT in a cohort of patients with CLBP. One hundred patients with chronic primary low back pain will be randomised to receive 12 sessions of SMT or placebo SMT over a 4-week period. Pain intensity and disability will be assessed as primary outcomes after completing the 4-week treatment (primary endpoint), and at 4-week and 12-week follow-ups. Baseline values of two pain questionnaires, lumbar pressure pain thresholds, concentrations of an inflammatory cytokine and expectations of pain relief will be entered as predictors of the response to SMT in a multiple regression model. Changes in these variables after treatment will be used in a second multiple regression model. The reference values of these predictors will be measured from 50 age and sex-matched healthy controls to allow interpretation of values in patients. Mixed analyses of variance will also be conducted to compare the primary outcomes and the predictors between groups (SMT vs placebo) over time (baseline vs post-treatment).

Ethics and dissemination
Ethical approval was granted by the Fundación Jiménez Díaz Clinical Research Ethics Committee.

Trial registration number NCT05162924.

Type de document:	Article
Date de dépôt:	01 mars 2023 20:09
Dernière modification:	01 mars 2023 20:11
Version du document déposé:	Version officielle de l'éditeur
URI:	https://depot-e.uqtr.ca/id/eprint/10508

Actions (administrateurs uniquement)

Éditer la notice